Inflammation markers in virologically suppressed HIV-Infected patients after switching to dolutegravir plus lamivudine vs continuing triple therapy: 48-week results in real-life setting

Francesca Lombardi; Simone Belmonti; Davide Moschese; Massimiliano Fabbiani; Alberto Borghetti; Arturo Ciccullo; Elena Visconti; Simona Di Giambenedetto

doi:10.1080/25787489.2022.2080625

Inflammation markers in virologically suppressed HIV-Infected patients after switching to dolutegravir plus lamivudine vs continuing triple therapy: 48-week results in real-life setting

Francesca Lombardi^*, Simone Belmonti, Davide Moschese, Massimiliano Fabbiani, Alberto Borghetti, Arturo Ciccullo, Elena Visconti, Simona Di Giambenedetto

^*Autore corrispondente per questo lavoro

Risultato della ricerca: Contributo in rivista › Articolo

Lingua originale	Inglese
pagine (da-a)	28-36
Numero di pagine	9
Rivista	HIV RESEARCH & CLINICAL PRACTICE
Volume	23
Numero di pubblicazione	1
DOI	https://doi.org/10.1080/25787489.2022.2080625
Stato di pubblicazione	Pubblicato - 2022

All Science Journal Classification (ASJC) codes

Malattie Infettive
Farmacologia (medica)

Keywords

3-Ring
Anti-HIV Agents
Biomarkers
HIV
HIV Infections
HIV-1
Heterocyclic Compounds
Humans
Inflammation
Interleukin-6
Lamivudine
Longitudinal Studies
Oxazines
Piperazines
Pyridones
Viral Load
dolutegravir
dual therapy
inflammation
inflammatory biomarkers
lamivudine

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.1080/25787489.2022.2080625

Altri file e collegamenti

Cita questo

Lombardi, F., Belmonti, S., Moschese, D., Fabbiani, M., Borghetti, A., Ciccullo, A., Visconti, E., & Di Giambenedetto, S. (2022). Inflammation markers in virologically suppressed HIV-Infected patients after switching to dolutegravir plus lamivudine vs continuing triple therapy: 48-week results in real-life setting. HIV RESEARCH & CLINICAL PRACTICE, 23(1), 28-36. https://doi.org/10.1080/25787489.2022.2080625

@article{49fc1c96bbb14af4be7a7fff5f0606fe,

title = "Inflammation markers in virologically suppressed HIV-Infected patients after switching to dolutegravir plus lamivudine vs continuing triple therapy: 48-week results in real-life setting",

keywords = "3-Ring, Anti-HIV Agents, Biomarkers, HIV, HIV Infections, HIV-1, Heterocyclic Compounds, Humans, Inflammation, Interleukin-6, Lamivudine, Longitudinal Studies, Oxazines, Piperazines, Pyridones, Viral Load, dolutegravir, dual therapy, inflammation, inflammatory biomarkers, lamivudine, 3-Ring, Anti-HIV Agents, Biomarkers, HIV, HIV Infections, HIV-1, Heterocyclic Compounds, Humans, Inflammation, Interleukin-6, Lamivudine, Longitudinal Studies, Oxazines, Piperazines, Pyridones, Viral Load, dolutegravir, dual therapy, inflammation, inflammatory biomarkers, lamivudine",

author = "Francesca Lombardi and Simone Belmonti and Davide Moschese and Massimiliano Fabbiani and Alberto Borghetti and Arturo Ciccullo and Elena Visconti and \{Di Giambenedetto\}, Simona",

year = "2022",

doi = "10.1080/25787489.2022.2080625",

language = "English",

volume = "23",

pages = "28--36",

journal = "HIV RESEARCH \& CLINICAL PRACTICE",

issn = "2578-7470",

publisher = "Taylor and Francis Ltd.",

number = "1",

}

Lombardi, F, Belmonti, S, Moschese, D, Fabbiani, M, Borghetti, A, Ciccullo, A, Visconti, E & Di Giambenedetto, S 2022, 'Inflammation markers in virologically suppressed HIV-Infected patients after switching to dolutegravir plus lamivudine vs continuing triple therapy: 48-week results in real-life setting', HIV RESEARCH & CLINICAL PRACTICE, vol. 23, n. 1, pagg. 28-36. https://doi.org/10.1080/25787489.2022.2080625

Inflammation markers in virologically suppressed HIV-Infected patients after switching to dolutegravir plus lamivudine vs continuing triple therapy: 48-week results in real-life setting. / Lombardi, Francesca; Belmonti, Simone; Moschese, Davide et al.
In: HIV RESEARCH & CLINICAL PRACTICE, Vol. 23, N. 1, 2022, pag. 28-36.

Risultato della ricerca: Contributo in rivista › Articolo

TY - JOUR

T1 - Inflammation markers in virologically suppressed HIV-Infected patients after switching to dolutegravir plus lamivudine vs continuing triple therapy: 48-week results in real-life setting

AU - Lombardi, Francesca

AU - Belmonti, Simone

AU - Moschese, Davide

AU - Fabbiani, Massimiliano

AU - Borghetti, Alberto

AU - Ciccullo, Arturo

AU - Visconti, Elena

AU - Di Giambenedetto, Simona

PY - 2022

Y1 - 2022

KW - 3-Ring

KW - Anti-HIV Agents

KW - Biomarkers

KW - HIV

KW - HIV Infections

KW - HIV-1

KW - Heterocyclic Compounds

KW - Humans

KW - Inflammation

KW - Interleukin-6

KW - Lamivudine

KW - Longitudinal Studies

KW - Oxazines

KW - Piperazines

KW - Pyridones

KW - Viral Load

KW - dolutegravir

KW - dual therapy

KW - inflammation

KW - inflammatory biomarkers

KW - lamivudine

KW - 3-Ring

KW - Anti-HIV Agents

KW - Biomarkers

KW - HIV

KW - HIV Infections

KW - HIV-1

KW - Heterocyclic Compounds

KW - Humans

KW - Inflammation

KW - Interleukin-6

KW - Lamivudine

KW - Longitudinal Studies

KW - Oxazines

KW - Piperazines

KW - Pyridones

KW - Viral Load

KW - dolutegravir

KW - dual therapy

KW - inflammation

KW - inflammatory biomarkers

KW - lamivudine

UR - https://publicatt.unicatt.it/handle/10807/214194

UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85133102196&origin=inward

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85133102196&origin=inward

U2 - 10.1080/25787489.2022.2080625

DO - 10.1080/25787489.2022.2080625

M3 - Article

SN - 2578-7470

VL - 23

SP - 28

EP - 36

JO - HIV RESEARCH & CLINICAL PRACTICE

JF - HIV RESEARCH & CLINICAL PRACTICE

IS - 1

ER -